Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1677251

registered interest
date	12/12/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cystic Fibrosis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if she will hold discussions with (a) the Cystic Fibrosis Trust and (b) other relevant stakeholders on the availability of (i) modular therapies and (ii) other treatments for cystic fibrosis through the NHS.
tabling member constituency	Belfast South
tabling member printed	Claire Hanna
uin	6633
answer	answer is ministerial correction date of answer 18/12/2023 answer text <p>The National Institute for Health and Care Excellence (NICE) is currently developing recommendations on whether the licensed cystic fibrosis modulator therapies can be recommended for routine funding by the National Health Service. NICE is responsible for leading engagement with interested parties in the development of its recommendations and we have no plans to hold separate discussions.</p><p>NICE has recently consulted on its draft guidance and continues to work with stakeholders to address the issues highlighted by its independent Appraisal Committee. The Department encourages stakeholders such as patients and representative organisations to continue to engage in the NICE evaluation process.</p><p>Under the terms of the interim access agreement between NHS England and Vertex, eligible children and adults with cystic fibrosis in England can continue to receive ongoing treatment and be initiated onto treatment with the licensed cystic fibrosis modulators, as clinically appropriate, while NICE concludes its evaluation. The availability of medicines in Wales, Scotland and Northern Ireland is a matter for the devolved administrations.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 18/12/2023 17:06:16 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4827 label Biography information for Claire Hanna

1677257

registered interest
date	12/12/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Health: Screening
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether the Monthly Diagnostic Data published by NHS England includes data on (a) pathology and (b) phlebotomy.
tabling member constituency	Easington
tabling member printed	Grahame Morris
uin	6441
answer	answer is ministerial correction date of answer 19/12/2023 answer text <p>NHS England does not currently include pathology and phlebotomy in their monthly published diagnostic datasets.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 19/12/2023 17:10:59 answering member 4044 label Biography information for Andrew Stephenson
tabling member	3973 label Biography information for Grahame Morris

1677260

registered interest
date	12/12/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Skin Diseases: Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether she is taking steps to monitor the effectiveness of NHS England’s guidance on Referral optimisation for people with skin conditions.
tabling member constituency	Bootle
tabling member printed	Peter Dowd
uin	6510
answer	answer is ministerial correction date of answer 18/12/2023 answer text <p>As advised in the Getting it Right First Time (GIRFT) national report on dermatology, published in August 2021, 56% of trusts reported that they had to wait for commissioner approval before prescribing drugs approved by the National Institute for Health and Care Excellence (NICE), and 12% of trusts said they had been told by clinical commissioning groups that they could not prescribe certain NICE-approved biologics for psoriasis at the time of NHS England’s data questionnaire in 2018/19.</p><p>During GIRFT’s subsequent deep dives into the 110 trusts with significant dermatology activity, it became apparent that there was ongoing variation in the way trusts adopt NICE guidelines. While some allow clinicians to prescribe drugs as soon as they are NICE approved, others have processes in place which can produce delays of more than a year in some cases.</p><p>GIRFT is aiming to publish trust- and system-level data for dermatology on the Model Health System in early 2024, enabling dermatology clinicians and managers to monitor their variation in provision of care, services, and treatments for skin disorders. Specific metrics for inflammatory skin disorders, including biologic prescribing for psoriasis and eczema, will be included. The aim is to use this data to inform the dermatology element of GIRFT’s Further Faster programme to help target unwarranted variation in care provision for inflammatory skin disease. The Further Faster programme supports providers to deliver rapid clinical transformation to reduce 52-week waits.</p><p>There are no plans to introduce specific targets to adopt the NHS England guidance on Referral Optimisation for people with skin conditions. The Outpatient Recovery &amp; Transformation Programme in NHS England will continue to promote the guidance through NHS England regional teams, integrated care boards and directly to provider organisations.</p><p>In addition, specific engagement events, such as the webinar delivered on 21 November 2023, will continue to reinforce the need for appropriate and timely referral optimisation across skin care pathways. The programme is working closely with GIRFT and the Further Faster teams to ensure that referral optimisation is seen as a valuable tool to effectively manage the skin care pathway. Through this effort to engage the system combined with the publication of consistent guidance and evidence across the whole skin care pathway, it is hoped that variation can be reduced, across pathway implementation.</p><p>It should be recognised that there may be appropriate clinical reasons for some regional or local variation, so it is important to ensure that all patients who need specialist skincare have equal access. The programme will look to review data over the course of the year to understand the impact and consider relevant next steps.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 6511 6512 6513 question first answered 18/12/2023 17:11:22 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4397 label Biography information for Peter Dowd

1677261

registered interest
date	12/12/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Skin Diseases: Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if her Department will set a target for the number of trusts to adopt the NHS England guidance on Referral optimisation for people with skin conditions.
tabling member constituency	Bootle
tabling member printed	Peter Dowd
uin	6511
answer	answer is ministerial correction date of answer 18/12/2023 answer text <p>As advised in the Getting it Right First Time (GIRFT) national report on dermatology, published in August 2021, 56% of trusts reported that they had to wait for commissioner approval before prescribing drugs approved by the National Institute for Health and Care Excellence (NICE), and 12% of trusts said they had been told by clinical commissioning groups that they could not prescribe certain NICE-approved biologics for psoriasis at the time of NHS England’s data questionnaire in 2018/19.</p><p>During GIRFT’s subsequent deep dives into the 110 trusts with significant dermatology activity, it became apparent that there was ongoing variation in the way trusts adopt NICE guidelines. While some allow clinicians to prescribe drugs as soon as they are NICE approved, others have processes in place which can produce delays of more than a year in some cases.</p><p>GIRFT is aiming to publish trust- and system-level data for dermatology on the Model Health System in early 2024, enabling dermatology clinicians and managers to monitor their variation in provision of care, services, and treatments for skin disorders. Specific metrics for inflammatory skin disorders, including biologic prescribing for psoriasis and eczema, will be included. The aim is to use this data to inform the dermatology element of GIRFT’s Further Faster programme to help target unwarranted variation in care provision for inflammatory skin disease. The Further Faster programme supports providers to deliver rapid clinical transformation to reduce 52-week waits.</p><p>There are no plans to introduce specific targets to adopt the NHS England guidance on Referral Optimisation for people with skin conditions. The Outpatient Recovery &amp; Transformation Programme in NHS England will continue to promote the guidance through NHS England regional teams, integrated care boards and directly to provider organisations.</p><p>In addition, specific engagement events, such as the webinar delivered on 21 November 2023, will continue to reinforce the need for appropriate and timely referral optimisation across skin care pathways. The programme is working closely with GIRFT and the Further Faster teams to ensure that referral optimisation is seen as a valuable tool to effectively manage the skin care pathway. Through this effort to engage the system combined with the publication of consistent guidance and evidence across the whole skin care pathway, it is hoped that variation can be reduced, across pathway implementation.</p><p>It should be recognised that there may be appropriate clinical reasons for some regional or local variation, so it is important to ensure that all patients who need specialist skincare have equal access. The programme will look to review data over the course of the year to understand the impact and consider relevant next steps.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 6510 6512 6513 question first answered 18/12/2023 17:11:22 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4397 label Biography information for Peter Dowd

1677262

registered interest
date	12/12/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Skin Diseases: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to page 85 of the Getting it Right First Time report on Dermatology, published by the NHS in August 2021, how many and what proportion of trusts are required to wait for commissioner approval before prescribing (a) NICE-approved biologics for psoriasis and (b) other NICE-approved drugs.
tabling member constituency	Bootle
tabling member printed	Peter Dowd
uin	6512
answer	answer is ministerial correction date of answer 18/12/2023 answer text <p>As advised in the Getting it Right First Time (GIRFT) national report on dermatology, published in August 2021, 56% of trusts reported that they had to wait for commissioner approval before prescribing drugs approved by the National Institute for Health and Care Excellence (NICE), and 12% of trusts said they had been told by clinical commissioning groups that they could not prescribe certain NICE-approved biologics for psoriasis at the time of NHS England’s data questionnaire in 2018/19.</p><p>During GIRFT’s subsequent deep dives into the 110 trusts with significant dermatology activity, it became apparent that there was ongoing variation in the way trusts adopt NICE guidelines. While some allow clinicians to prescribe drugs as soon as they are NICE approved, others have processes in place which can produce delays of more than a year in some cases.</p><p>GIRFT is aiming to publish trust- and system-level data for dermatology on the Model Health System in early 2024, enabling dermatology clinicians and managers to monitor their variation in provision of care, services, and treatments for skin disorders. Specific metrics for inflammatory skin disorders, including biologic prescribing for psoriasis and eczema, will be included. The aim is to use this data to inform the dermatology element of GIRFT’s Further Faster programme to help target unwarranted variation in care provision for inflammatory skin disease. The Further Faster programme supports providers to deliver rapid clinical transformation to reduce 52-week waits.</p><p>There are no plans to introduce specific targets to adopt the NHS England guidance on Referral Optimisation for people with skin conditions. The Outpatient Recovery &amp; Transformation Programme in NHS England will continue to promote the guidance through NHS England regional teams, integrated care boards and directly to provider organisations.</p><p>In addition, specific engagement events, such as the webinar delivered on 21 November 2023, will continue to reinforce the need for appropriate and timely referral optimisation across skin care pathways. The programme is working closely with GIRFT and the Further Faster teams to ensure that referral optimisation is seen as a valuable tool to effectively manage the skin care pathway. Through this effort to engage the system combined with the publication of consistent guidance and evidence across the whole skin care pathway, it is hoped that variation can be reduced, across pathway implementation.</p><p>It should be recognised that there may be appropriate clinical reasons for some regional or local variation, so it is important to ensure that all patients who need specialist skincare have equal access. The programme will look to review data over the course of the year to understand the impact and consider relevant next steps.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 6510 6511 6513 question first answered 18/12/2023 17:11:22 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4397 label Biography information for Peter Dowd

1677263

registered interest
date	12/12/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Skin Diseases: Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether her Department is taking steps to assess the level of regional variation in access to (a) care, (b) services and (c) treatment for patients with inflammatory skin conditions.
tabling member constituency	Bootle
tabling member printed	Peter Dowd
uin	6513
answer	answer is ministerial correction date of answer 18/12/2023 answer text <p>As advised in the Getting it Right First Time (GIRFT) national report on dermatology, published in August 2021, 56% of trusts reported that they had to wait for commissioner approval before prescribing drugs approved by the National Institute for Health and Care Excellence (NICE), and 12% of trusts said they had been told by clinical commissioning groups that they could not prescribe certain NICE-approved biologics for psoriasis at the time of NHS England’s data questionnaire in 2018/19.</p><p>During GIRFT’s subsequent deep dives into the 110 trusts with significant dermatology activity, it became apparent that there was ongoing variation in the way trusts adopt NICE guidelines. While some allow clinicians to prescribe drugs as soon as they are NICE approved, others have processes in place which can produce delays of more than a year in some cases.</p><p>GIRFT is aiming to publish trust- and system-level data for dermatology on the Model Health System in early 2024, enabling dermatology clinicians and managers to monitor their variation in provision of care, services, and treatments for skin disorders. Specific metrics for inflammatory skin disorders, including biologic prescribing for psoriasis and eczema, will be included. The aim is to use this data to inform the dermatology element of GIRFT’s Further Faster programme to help target unwarranted variation in care provision for inflammatory skin disease. The Further Faster programme supports providers to deliver rapid clinical transformation to reduce 52-week waits.</p><p>There are no plans to introduce specific targets to adopt the NHS England guidance on Referral Optimisation for people with skin conditions. The Outpatient Recovery &amp; Transformation Programme in NHS England will continue to promote the guidance through NHS England regional teams, integrated care boards and directly to provider organisations.</p><p>In addition, specific engagement events, such as the webinar delivered on 21 November 2023, will continue to reinforce the need for appropriate and timely referral optimisation across skin care pathways. The programme is working closely with GIRFT and the Further Faster teams to ensure that referral optimisation is seen as a valuable tool to effectively manage the skin care pathway. Through this effort to engage the system combined with the publication of consistent guidance and evidence across the whole skin care pathway, it is hoped that variation can be reduced, across pathway implementation.</p><p>It should be recognised that there may be appropriate clinical reasons for some regional or local variation, so it is important to ensure that all patients who need specialist skincare have equal access. The programme will look to review data over the course of the year to understand the impact and consider relevant next steps.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 6510 6511 6512 question first answered 18/12/2023 17:11:22 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4397 label Biography information for Peter Dowd

1677288

registered interest
date	12/12/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Duty of Candour Review
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether she has had discussions with the Secretary of State for Justice on her Department's duty of candour review for health and social care providers.
tabling member constituency	Denton and Reddish
tabling member printed	Andrew Gwynne
uin	6450
answer	answer is ministerial correction date of answer 18/12/2023 answer text <p>Ahead of publishing the Terms of Reference for the review on 6 December 2023, we consulted all members of the Home Affairs Committee, including my rt. Hon. Friend, the Secretary of State for Justice, on the Department’s planned approach to review the statutory duty of candour.</p> answering member constituency Lewes answering member printed Maria Caulfield question first answered 18/12/2023 17:04:37 answering member 4492 label Biography information for Maria Caulfield
tabling member	1506 label Biography information for Andrew Gwynne

1677289

registered interest
date	12/12/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Community Diagnostic Centres
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if she will publish a list of every community diagnostic centre in England split into (a) permanent and (b) temporary locations.
tabling member constituency	Birmingham, Edgbaston
tabling member printed	Preet Kaur Gill
uin	6515
answer	answer is ministerial correction date of answer 18/12/2023 answer text <p>The Government has previously published several lists setting out those community diagnostic centres (CDCs) that are currently operational across England and intends to update the latest published list in due course. As of December 2023, there are 136 CDCs currently operational that have delivered over five million additional tests since July 2021.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 18/12/2023 16:22:49 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4603 label Biography information for Preet Kaur Gill

1677290

registered interest
date	12/12/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Community Diagnostic Centres
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many and what proportion of patients have been treated per community diagnostic centre as of 12 December 2023.
tabling member constituency	Birmingham, Edgbaston
tabling member printed	Preet Kaur Gill
uin	6516
answer	answer is ministerial correction date of answer 18/12/2023 answer text <p>The data requested is not held.</p><p>As of November 2023, there are 136 community diagnostic centres (CDCs) currently operational that have delivered over five million additional tests since July 2021.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 18/12/2023 17:12:32 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4603 label Biography information for Preet Kaur Gill

1677314

registered interest
date	12/12/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Influenza: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many and what proportion of the eligible population received the NHS flu vaccine by 12 December in each of the last 10 years.
tabling member constituency	Birmingham, Edgbaston
tabling member printed	Preet Kaur Gill
uin	6518
answer	answer is ministerial correction date of answer 18/12/2023 answer text <p>The information is not held in the format requested.</p> answering member constituency Lewes answering member printed Maria Caulfield question first answered 18/12/2023 14:09:44 answering member 4492 label Biography information for Maria Caulfield
tabling member	4603 label Biography information for Preet Kaur Gill